Janus Henderson Group’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Janus Henderson Group’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-41,862	Closed	-$423K	–	2822
2022 Q4	$423K	Sell	41,862 -41,568	-50%	-$416K	﹤0.01%	1797
2022 Q3	$828K	Buy	83,430 +41,715	+100%	+$412K	﹤0.01%	1738
2022 Q2	$412K	Buy	+41,715	New	+$409K	﹤0.01%	1884

Janus Henderson Group's BIOT Position: Q1 2023 in Review

Janus Henderson Group sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 41,862 shares — an estimated $423K sold.

Janus Henderson Group first reported a position in BIOT in Q2 2022 and held it in 3 quarters. The position peaked at $828K in Q3 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Janus Henderson Group reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Janus Henderson Group sold 41,862 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $423K.
Janus Henderson Group first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2022 and held it in 3 quarters.
Janus Henderson Group's Biotech Acquisition Company Class A Ordinary Shares position peaked at $828K in Q3 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Janus Henderson Group's 13F filing for Q1 2023, filed 15 May 2023.